Arellano BRH, Torres VA, García UC, Domínguez MA

Language: Spanish
References: 18
Page: 399-403
PDF size: 240.51 Kb.

ABSTRACT

The carcinoid tumor of ovary is rare (1%), being a slow growth tumor, generally being well differentiated, which can stay without diagnosis for many months or even years before having metastatized. The most severe complicacion of this tumor is a carcinoic crisis. The diagnosis is done with tumoral biomarkers including neuronal specific enolase, chromogranine Q, seric serotonine, and 5 H-hidroxiindolacetic acid. The treatment requires energic management with ocreotid. When this crsis is not diagnosed and treat on time, the mortality is higher. Here we describe a clinical case of a 59 year old woman with clear menifestations of the carcinoid syndrome, including cardiac affection and renal insufficiency.

REFERENCES

1. Kaltsas GA, Besser GM & Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Reviews 2004;25:458-511.

2. Somshekar G, Milton R, Davidson L, Thorpe A. Facial Flushing Due to Recurrent Bronchial Carcinoid. Ann Thorac Surg 2007;83:1196 -9.

3. Warner RR, Kirschner PA, Warner GM. Serotonin production by bronchial adenomas without the carcinoid syndrome. JAMA 1961;178: 1175-9.

4. Feldman JM, Lee EM. Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid. Am J Clin Nutr 1985;42:639-43.

5. Kema IP, de Vries EG, Muskiet FA. Measurement of 5-HIAA in urine. Annals of Clinical Biochemistry 1995;32:102-4.

6. Kema IP, Meijer WG, Meiborg G, et al. Profiling of tryptophanrelated plasma indoles in patients with carcinoid tumors by automated, on-line, solid-phase extraction and HPLC with fluorescence detection. Clinical Chemistry 2001;47:1811- 20.

7. Kema IP, de Vries EG, Muskiet FA. Clinical chemistry of serotonin and metabolites. J Ch Bio Scien Appl 2000;747:33-48.

8. Meijer WG, Kema IP, Volmer M, et al. Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clinical Chemistry 2000;46:1588-96.

9. Kema IP, de Vries EG, Slooff MJ, et al. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clinical Chemistry 1994;40:86-95.

10. Wouter WH. Biochemistry of neuroendocrine tumours. Best Practice & Research Clinical Endocrinology & Metabolism 2007;21(1):33-41.

11. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion 2000;62(suppl 1):33-38.

12. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Met 1997;82:2622-28.

13. Baudin E, Gigliotti A, Ducreux M, et al. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. BJ Cancer 1998;78:1102-7.

14. Bajetta E, Ferrari L, Martinetti A, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer 1999;86:858-65.

15. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007;19:25-31.

16. Cancer Medicine Neoplasms of the Neuroendocrine system. 5th ed. Holland.

17. Bethesda Handbook of Clinical Oncology. Endocrine tumors. 2th ed. Philadelphia: Lippincott Williams and Wilkins, 2005;pp:454-72.

18. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: VT DeVita Jr, S Hellman, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia: Lippincott Williams and Wilkins, 2005;pp:1559-74.